[1] Shen T, Liu Y, Shang J, et al. Incidence and etiology of drug-induced liver injury in mainland China[J]. Gastroenterology, 2019, 156(8): 2230-2241.e2211.
[2] Björnsson E S, Bergmann O M, Björnsson H K, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland[J]. Gastroenterology, 2013, 144(7): 1419-1425, 1425.e1411-1413; quiz e1419-1420.
[3] DiPaola F, Molleston J P, Gu J, et al. Antimicrobials and antiepileptics are the leading causes of idiosyncratic drug-induced liver injury in American children[J]. J Pediatr Gastroenterol Nutr, 2019, 69(2): 152-159.
[4] Fontana R J, Liou I, Reuben A, et al. AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury[J]. Hepatology (Baltimore, Md), 2023, 77(3): 1036-1065.
[5] Hoofnagle J H, Bonkovsky H L, Phillips E J, et al. HLA-B*35:01 and green tea-induced liver injury[J]. Hepatology (Baltimore, Md), 2021, 73(6): 2484-2493.
[6] Bessone F, García-Cortés M, Medina-Caliz I, et al. Herbal and dietary supplements-induced liver injury in Latin America: experience from the LATINDILI network[J]. Clin Gastroenterol Hepatol, 2022, 20(3): e548-e563.
[7] Yoshikawa Y, Imamura M, Yamaoka K, et al. A case with life-threatening secondary sclerosing cholangitis caused by nivolumab[J]. Clin J Gastroenterol, 2021, 14(1): 283-287.
[8] Björnsson E S, Medina-Caliz I, Andrade R J, et al. Setting up criteria for drug-induced autoimmune-like hepatitis through a systematic analysis of published reports[J]. Hepatol Commun, 2022, 6(8): 1895-1909.
[9] Kulkarni A V, Hanchanale P, Prakash V, et al. Tinospora cordifolia (giloy)-induced liver injury during the COVID-19 pandemic-multicenter nationwide study from India[J]. Hepatol Commun, 2022, 6(6): 1289-1300.
[10] Efe C, Kulkarni A V, Beretta-Piccoli B T, et al. Liver injury after SARS-CoV-2 vaccination: Features of immune-mediated hepatitis, role of corticosteroid therapy and outcome[J]. Hepatology (Baltimore, Md), 2022, 76(6): 1576-1586.
[11] Alpers D H, Lewis J H, Hunt C M, et al. Clinical pattern of tolvaptan-associated liver injury in trial participants with autosomal dominant polycystic kidney disease (ADPKD): an analysis of pivotal clinical trials[J]. Am J Kidney Dis, 2023, 81(3): 281-293.e281.
[12] Kleiner D E, Chalasani N P, Lee W M, et al. Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations[J]. Hepatology (Baltimore, Md), 2014, 59(2): 661-670.
[13] Devarbhavi H, Kurien S S, Kumar Y, et al. Comparison of roussel-uclaf causality assessment method (RUCAM) versus revised electronic causality assessment method (RECAM)-analysis of 100 cases from an indian registry[J]. Hepatology (Baltimore, Md),2022: S1446-S1446.
[14] Cirulli E T, Nicoletti P, Abramson K, et al. A missense variant in PTPN22 is a risk factor for drug-induced liver injury[J]. Gastroenterology, 2019, 156(6): 1707-1716.e1702.
[15] Church R J, Kullak-Ublick G A, Aubrecht J, et al. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: an international collaborative effort[J]. Hepatology (Baltimore, Md), 2019, 69(2): 760-773.
[16] Llewellyn H P, Vaidya V S, Wang Z, et al. Evaluating the sensitivity and specificity of promising circulating biomarkers to diagnose liver injury in humans[J]. Toxicol Sci, 2021, 181(1): 23-34.
[17] Hayashi P H, Rockey D C, Fontana R J, et al. Death and liver transplantation within 2 years of onset of drug-induced liver injury[J]. Hepatology (Baltimore, Md), 2017, 66(4): 1275-1285.
[18] Ghabril M, Gu J, Yoder L, et al. Development and validation of a model consisting of comorbidity burden to calculate risk of death within 6 months for patients with suspected drug-induced liver injury[J]. Gastroenterology, 2019, 157(5): 1245-1252.e1243.
[19] Robles-Diaz M, Lucena M I, Kaplowitz N, et al. Use of Hy′s law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury[J]. Gastroenterology, 2014, 147(1): 109-118.e105.
[20] Lewis J H, Jadoul M, Block G A, et al. Effects of bardoxolone methyl on hepatic enzymes in patients with type 2 diabetes mellitus and stage 4 CKD[J]. Clin Transl Sci, 2021, 14(1): 299-309.
[21] Andrade R J, Lucena M I, Fernández M C, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period[J]. Gastroenterology, 2005, 129(2): 512-521.
[22] Björnsson E S, Vucic V, Stirnimann G, et al. Role of corticosteroids in drug-induced liver injury. a systematic review[J]. Front Pharmacol, 2022, 13: 820724.
[23] Karkhanis J, Verna E C, Chang M S, et al. Steroid use in acute liver failure[J]. Hepatology (Baltimore, Md), 2014, 59(2): 612-621.
[24] Swanson L A, Kassab I, Tsung I, et al. Liver injury during durvalumab-based immunotherapy is associated with poorer patient survival: a retrospective analysis[J]. Frontiers in Oncology, 2022, 12: 984940.
[25] Lee W M, Hynan L S, Rossaro L, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure[J]. Gastroenterology, 2009, 137(3): 856-864, 864.e851.
[26] Squires R H, Dhawan A, Alonso E, et al. Intravenous N-acetylcysteine in pediatric patients with nonacetaminophen acute liver failure: a placebo-controlled clinical trial[J]. Hepatology (Baltimore, Md), 2013, 57(4): 1542-1549.
[27] Robles-Díaz M, Nezic L, Vujic-Aleksic V, et al. Role of ursodeoxycholic acid in treating and preventing idiosyncratic drug-induced liver injury. A systematic review[J]. Front Pharmacol, 2021, 12: 744488.
[28] Perrott J, Murphy N G, Zed P J. L-carnitine for acute valproic acid overdose: a systematic review of published cases[J]. Ann Pharmacother, 2010, 44(7-8): 1287-1293.
[29] Richardson P G, Riches M L, Kernan N A, et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure[J]. Blood, 2016, 127(13): 1656-1665.
[30] Niu H, Sanabria-Cabrera J, Alvarez-Alvarez I, et al. Prevention and management of idiosyncratic drug-induced liver injury: systematic review and meta-analysis of randomised clinical trials[J]. Pharmacological Research, 2021, 164: 105404. |
